MDxHealth Strengthens Its Leadership with New Board Appointment
MDxHealth SA (NASDAQ: MDXH), a prominent player in precision diagnostics, recently announced the appointment of Michael Holder to its Board of Directors. He will serve as the Chair of the Audit Committee, stepping in for Regine Slagmulder, who completed her term. This strategic change is significant for the company as it continues to innovate in molecular diagnostics.
Experience and Expertise of Michael Holder
Michael Holder brings over three decades of varied experience to his new role. His extensive background includes positions such as board member, CEO, and CFO across both public and private sectors in biotechnology, medical technology, health technology, pharmaceuticals, and wellness. His capabilities in corporate strategy, mergers and acquisitions, governance, and sales enhance the board's expertise. Notably, he led a private investment company worth $250 million and most recently held the CEO position at Sensable Health, an AI-focused wellness initiative.
CEO's Enthusiasm for New Appointment
Michael K. McGarrity, the CEO of MDxHealth, expressed his enthusiasm regarding Holder's appointment, emphasizing the value his extensive experience will bring. With Holder’s diverse background, McGarrity believes he will significantly contribute to the company's growth, especially in the rapidly evolving urology market.
Management Changes at MDxHealth
Alongside the board appointment, MDxHealth also announced a management transition. Ron Kalfus resigned from his Chief Financial Officer role to explore new opportunities. He will continue until his departure on July 30, 2025, and the CFO responsibilities will temporarily shift to Scott McMahan, who currently serves as Vice President of Finance and Accounting.
Acknowledgment of Contributions
In addressing these changes, McGarrity thanked Kalfus for his invaluable contributions over the past six years, highlighting the significant growth under his fiscal leadership. The team expresses their best wishes as Kalfus embarks on his next career journey.
Chairman of the Board's Statement
Koen Hoffman, the Board Chair, welcomed Holder and extended gratitude towards Slagmulder and Kalfus for their extensive service. Their dedication has propelled MDxHealth forward with integrity and professionalism, marking a pivotal era in the company's trajectory.
About MDxHealth
MDxHealth specializes in providing critical genomic insights to personalize cancer diagnostics and treatment. Their innovative tests utilize proprietary techniques in genomics and molecular biology, assisting medical professionals in diagnosing and predicting the progression of urologic cancers and conditions. With headquarters in Irvine, California, and operations extending to Plano, Texas, along with its European base in Herstal, Belgium, MDxHealth remains committed to advancing healthcare through precision diagnostics.
Frequently Asked Questions
What role is Michael Holder taking on at MDxHealth?
Michael Holder has been appointed as the Chair of the Audit Committee on the Board of Directors at MDxHealth.
Why did Ron Kalfus resign from his position?
Ron Kalfus resigned to pursue other career opportunities but will remain with the company until July 30, 2025.
Who will take over CFO responsibilities after Kalfus?
Scott McMahan, Vice President of Finance and Accounting, will assume CFO responsibilities on an interim basis.
What experience does Michael Holder bring to MDxHealth?
He has over 30 years of experience in various executive roles across biotech, medtech, and pharma, specializing in corporate strategy and financial governance.
What is MDxHealth's main focus as a company?
MDxHealth focuses on precision diagnostics, particularly in the area of urologic cancers, providing actionable genomic information to healthcare providers.
